StreetInsider.com News Articles

Form S-8 Rani Therapeutics Holdin

Wed, 15 Jul 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260715/26774921.html

Form S-8 Rani Therapeutics Holdin

Wed, 15 Jul 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260715/26774921.html

Rani Therapeutics oral obesity drug tops subcutaneous exposure in Phase 1a

Wed, 15 Jul 2026 08:00:57 -0400

Rani Therapeutics Holdings (Nasdaq: RANI) reported initial Phase 1a data for RT-114, an oral capsule delivering PG-102, a GLP-1/GLP-2 dual agonist developed in collaboration with ProGen Co., Ltd. for the treatment of obesity.

In the single-dose, open-label study, 30 healthy volunteers received a 12 mg dose of PG-102 either orally via the RaniPill Capsule or by subcutaneous injection. Oral RT-114 achieved systemic exposure greater than 150% relative to the matched subcutaneous dose. Elimination half-life was similar between the two groups, at 5.6 days for oral RT-114 and 5.3 days for subcutaneous PG-102.

No serious adverse events were reported in either arm, and

Rani Therapeutics oral obesity drug tops subcutaneous exposure in Phase 1a

Wed, 15 Jul 2026 08:00:57 -0400

No serious adverse events were reported in either arm, and

Rani Therapeutics oral obesity drug tops subcutaneous exposure in Phase 1a

Wed, 15 Jul 2026 08:00:57 -0400

No serious adverse events were reported in either arm, and

Rani Therapeutics oral obesity drug tops subcutaneous exposure in Phase 1a

Wed, 15 Jul 2026 08:00:57 -0400

No serious adverse events were reported in either arm, and

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

Wed, 15 Jul 2026 08:00:00 -0400

RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102
No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with the GLP-1/GLP-2 agonist class of therapeutics
Phase 1a study expanded with an additional cohort to further define the oral-to-subcutaneous pharmacokinetic relationship ahead of a planned Phase 1b repeat-dose study in patients with obesity

SAN JOSE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today reported positive initial data from the ongoing

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

Wed, 15 Jul 2026 08:00:00 -0400

RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102
No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with the GLP-1/GLP-2 agonist class of therapeutics
Phase 1a study expanded with an additional cohort to further define the oral-to-subcutaneous pharmacokinetic relationship ahead of a planned Phase 1b repeat-dose study in patients with obesity

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

Wed, 15 Jul 2026 08:00:00 -0400

RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102
No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with the GLP-1/GLP-2 agonist class of therapeutics
Phase 1a study expanded with an additional cohort to further define the oral-to-subcutaneous pharmacokinetic relationship ahead of a planned Phase 1b repeat-dose study in patients with obesity

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

Wed, 15 Jul 2026 08:00:00 -0400

RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102
No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with the GLP-1/GLP-2 agonist class of therapeutics
Phase 1a study expanded with an additional cohort to further define the oral-to-subcutaneous pharmacokinetic relationship ahead of a planned Phase 1b repeat-dose study in patients with obesity

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

Wed, 15 Jul 2026 08:00:00 -0400

RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102
No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with the GLP-1/GLP-2 agonist class of therapeutics
Phase 1a study expanded with an additional cohort to further define the oral-to-subcutaneous pharmacokinetic relationship ahead of a planned Phase 1b repeat-dose study in patients with obesity

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

Wed, 15 Jul 2026 08:00:00 -0400

RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102
No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with the GLP-1/GLP-2 agonist class of therapeutics
Phase 1a study expanded with an additional cohort to further define the oral-to-subcutaneous pharmacokinetic relationship ahead of a planned Phase 1b repeat-dose study in patients with obesity

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

Wed, 15 Jul 2026 08:00:00 -0400

RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102
No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with the GLP-1/GLP-2 agonist class of therapeutics
Phase 1a study expanded with an additional cohort to further define the oral-to-subcutaneous pharmacokinetic relationship ahead of a planned Phase 1b repeat-dose study in patients with obesity

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

Wed, 15 Jul 2026 08:00:00 -0400

RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102
No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with the GLP-1/GLP-2 agonist class of therapeutics
Phase 1a study expanded with an additional cohort to further define the oral-to-subcutaneous pharmacokinetic relationship ahead of a planned Phase 1b repeat-dose study in patients with obesity

Rani Therapeutics and PegBio enter obesity drug collaboration

Thu, 09 Jul 2026 16:06:12 -0400

Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) announced a research and development collaboration with PegBio Co., Ltd. to explore oral delivery of multiple obesity and metabolic disease drug candidates using Rani's RaniPill® platform, according to a press release issued July 9, 2026.

Under the agreement, the two companies will collaborate on preclinical development of RaniPill formulations for multiple molecules from PegBio's obesity and metabolic disease portfolio. The goal is to identify candidates suitable for advancement into clinical development.

The collaboration adds to Rani's existing obesity programs, which include RT-114, a GLP-1/GLP-2 dual agonist developed in partnership with ProGen that is currently in a

Rani Therapeutics and PegBio enter obesity drug collaboration

Thu, 09 Jul 2026 16:06:12 -0400

The collaboration adds to Rani's existing obesity programs, which include RT-114, a GLP-1/GLP-2 dual agonist developed in partnership with ProGen that is currently in a

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

Thu, 09 Jul 2026 16:05:00 -0400